Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
Keiko Imamura, Yuishin Izumi, Makiko Nagai, et al.
EClinicalMedicine (2022) Vol. 53, pp. 101707-101707
Open Access | Times Cited: 21

Showing 21 citing articles:

New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
JingSi Jiang, Yan Wang, Min Deng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 50
Induced Pluripotent Stem Cells and Their Applications in Amyotrophic Lateral Sclerosis
Hongmei Du, Zijun Huo, Yanchun Chen, et al.
Cells (2023) Vol. 12, Iss. 6, pp. 971-971
Open Access | Times Cited: 20
Advances and challenges in modeling inherited peripheral neuropathies using iPSCs
Jonas Van Lent, Robert Prior, Gonzalo Pérez Siles, et al.
Experimental & Molecular Medicine (2024) Vol. 56, Iss. 6, pp. 1348-1364
Open Access | Times Cited: 8
Clinical trials in-a-dish for cardiovascular medicine
Xuekun Wu, Kyle Swanson, Zehra Yıldırım, et al.
European Heart Journal (2024)
Closed Access | Times Cited: 7
iPS cell therapy 2.0: Preparing for next‐generation regenerative medicine
Kelvin K. Hui, Shinya Yamanaka
BioEssays (2024)
Closed Access | Times Cited: 5
ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline
Tatsuto Hamatani, Naoki Atsuta, Fumiya Sano, et al.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2024) Vol. 25, Iss. 3-4, pp. 388-399
Open Access | Times Cited: 4
Drug repurposing in amyotrophic lateral sclerosis (ALS)
Emily Carroll, Jakub Scaber, K. Huber, et al.
Expert Opinion on Drug Discovery (2025)
Open Access
The role of autophagy in the pathogenesis and treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)
Jimmy Beckers, Philip Van Damme
Autophagy Reports (2025) Vol. 4, Iss. 1
Open Access
Exploiting Host Kinases to Combat Dengue Virus Infection and Disease
Natasha M. Bourgeois, Ling Wei, Alexis Kaushansky, et al.
Antiviral Research (2025), pp. 106172-106172
Closed Access
Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis
Hideyuki Okano, Satoru Morimoto, Chris Kato, et al.
Journal of Neurochemistry (2023) Vol. 167, Iss. 5, pp. 603-614
Open Access | Times Cited: 9
Specific vulnerability of iPSC-derived motor neurons with TDP-43 gene mutation to oxidative stress
Asako Onda-Ohto, Minami Hasegawa-Ogawa, Hiromasa Matsuno, et al.
Molecular Brain (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 8
Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review
Rosa Luisa Potenza, Monica Armida, Patrizia Popoli
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1751-1751
Open Access | Times Cited: 3
Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
Loreto Martínez-González, Ana Martı́nez
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 2, pp. 141-160
Open Access | Times Cited: 7
Current neuroprotective therapies and future prospects for motor neuron disease
Laura J. Evans, David O’Brien, Pamela J. Shaw
International review of neurobiology (2024), pp. 327-384
Closed Access | Times Cited: 1
Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study
Keiko Imamura, Yuishin Izumi, Naohiro Egawa, et al.
BMJ Open (2024) Vol. 14, Iss. 10, pp. e082142-e082142
Open Access | Times Cited: 1
Pluripotent Stem Cells in Disease Modeling and Drug Discovery for Myotonic Dystrophy Type 1
Noémie M. L. P. Bérenger-Currias, Cécile Martinat, Sandrine Baghdoyan
Cells (2023) Vol. 12, Iss. 4, pp. 571-571
Open Access | Times Cited: 2
New developments in pre-clinical models of ALS to guide translation
Lenja De Cock, Valérie Bercier, Ludo Van Den Bosch
International review of neurobiology (2024), pp. 477-524
Closed Access
Discovery of 5-phenyl-3-ureidothiophene-2-carboxamides as protective agents for ALS patient iPSC-derived motor neurons
Haruhiko Hattori, Kazuya Osumi, Masamichi Tanaka, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 113, pp. 129935-129935
Closed Access
Discovery of Novel Inhibitors against ALS-Related SOD1(A4V) Aggregation through the Screening of a Chemical Library Using Differential Scanning Fluorimetry (DSF)
Μαρία Γιαννάκου, Ifigeneia Akrani, Angeliki Tsoka, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1286-1286
Open Access
Chronic Oxidative Stress and Stress Granule Formation in UBQLN2 ALS Neurons: Insights into Neuronal Degeneration and Potential Therapeutic Targets
Ao Gu, Yiti Zhang, Jianfeng He, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13448-13448
Open Access
Immunotherapy for Neurodegenerative Movement Disorders
R. Lee Mosley, Maamoon Saleh, Katherine E. Olson
NeuroImmune Pharmacology and Therapeutics (2024), pp. 943-973
Closed Access
Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes
Max Stevenson, Norah K. Algarzae, Charbel Moussa
Frontiers in Dementia (2024) Vol. 3
Open Access
Page 1

Scroll to top